Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
larger decrease » marked decrease (Expand Search)
alter decrease » water decreases (Expand Search), teer decrease (Expand Search), alter disease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
larger decrease » marked decrease (Expand Search)
alter decrease » water decreases (Expand Search), teer decrease (Expand Search), alter disease (Expand Search)
-
461
-
462
-
463
-
464
-
465
-
466
-
467
-
468
Socio-demographic characteristics of women in study sample (means except as noted).
Published 2025Subjects: -
469
Regression model summary outputs: Skilled delivery with MAMA kit (Binary exposure.).
Published 2025Subjects: -
470
-
471
Frequencies: Skilled delivery & skilled delivery with MAMA kit by exposure to remittances.
Published 2025Subjects: -
472
-
473
-
474
Regression model summary outputs: Skilled delivery with MAMA kit (Continuous exposure).
Published 2025Subjects: -
475
-
476
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
477
-
478
-
479
Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
480
Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”